A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.
Identifieur interne : 000E18 ( PubMed/Checkpoint ); précédent : 000E17; suivant : 000E19A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.
Auteurs : Christin Müller [Allemagne] ; Vera Ulyanova [Russie] ; Olga Ilinskaya [Russie] ; Stephan Pleschka [Allemagne] ; Raihan Shah Mahmud [Russie]Source :
- BioNanoScience [ 2191-1630 ] ; 2017.
Abstract
RNA viruses cause most of the dangerous communicable diseases. Due to their high mutation rates, RNA viruses quickly evade selective pressures and can adapt to a new host. Therefore, new antiviral approaches are urgently needed, which target more than one specific virus variant and which would optimally prevent development of viral resistance. Among the family of coronaviruses (CoV), several human pathogenic strains (HCoV) are known to cause respiratory diseases and are implied in enteric diseases. While most strains contribute to common cold-like illnesses, others lead to severe infections. One of these viruses is the newly emerged (2012), highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) of zoonotic origin. MERS-CoV causes a severe respiratory infection with a high mortality rate of 35 %. There is no specific treatment or infection prevention available. Here, we show that the bacterial ribonuclease Binase is able to inhibit the replication of MERS-CoV and of the low-pathogenic human coronavirus 229E (HCoV-229E) in cell culture. We demonstrate that at non-toxic concentrations, Binase decreased the titers of MERS-CoV and HCoV-229E. On a molecular level, Binase treatment reduced (i) the viral subgenomic RNAs and (ii) the viral nucleocapsidprotein (N) and non-structural protein 13 (nsp13) accumulation. Furthermore, we show that the quantity of the replication/transcription complexes within the infected cells is diminished. Thus, the data obtained might allow further development of new anti-coronaviral approaches affecting viral replication, independent of the specific virus strain.
DOI: 10.1007/s12668-016-0341-7
PubMed: 32219056
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32219056Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.</title><author><name sortKey="Muller, Christin" sort="Muller, Christin" uniqKey="Muller C" first="Christin" last="Müller">Christin Müller</name><affiliation wicri:level="1"><nlm:affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen</wicri:regionArea><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion></affiliation></author><author><name sortKey="Ulyanova, Vera" sort="Ulyanova, Vera" uniqKey="Ulyanova V" first="Vera" last="Ulyanova">Vera Ulyanova</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author><author><name sortKey="Ilinskaya, Olga" sort="Ilinskaya, Olga" uniqKey="Ilinskaya O" first="Olga" last="Ilinskaya">Olga Ilinskaya</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author><author><name sortKey="Pleschka, Stephan" sort="Pleschka, Stephan" uniqKey="Pleschka S" first="Stephan" last="Pleschka">Stephan Pleschka</name><affiliation wicri:level="1"><nlm:affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen</wicri:regionArea><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion></affiliation></author><author><name sortKey="Shah Mahmud, Raihan" sort="Shah Mahmud, Raihan" uniqKey="Shah Mahmud R" first="Raihan" last="Shah Mahmud">Raihan Shah Mahmud</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:32219056</idno><idno type="pmid">32219056</idno><idno type="doi">10.1007/s12668-016-0341-7</idno><idno type="wicri:Area/PubMed/Corpus">000E29</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E29</idno><idno type="wicri:Area/PubMed/Curation">000E29</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E29</idno><idno type="wicri:Area/PubMed/Checkpoint">000E18</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.</title><author><name sortKey="Muller, Christin" sort="Muller, Christin" uniqKey="Muller C" first="Christin" last="Müller">Christin Müller</name><affiliation wicri:level="1"><nlm:affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen</wicri:regionArea><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion></affiliation></author><author><name sortKey="Ulyanova, Vera" sort="Ulyanova, Vera" uniqKey="Ulyanova V" first="Vera" last="Ulyanova">Vera Ulyanova</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author><author><name sortKey="Ilinskaya, Olga" sort="Ilinskaya, Olga" uniqKey="Ilinskaya O" first="Olga" last="Ilinskaya">Olga Ilinskaya</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author><author><name sortKey="Pleschka, Stephan" sort="Pleschka, Stephan" uniqKey="Pleschka S" first="Stephan" last="Pleschka">Stephan Pleschka</name><affiliation wicri:level="1"><nlm:affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen</wicri:regionArea><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion><wicri:noRegion>35392 Giessen</wicri:noRegion></affiliation></author><author><name sortKey="Shah Mahmud, Raihan" sort="Shah Mahmud, Raihan" uniqKey="Shah Mahmud R" first="Raihan" last="Shah Mahmud">Raihan Shah Mahmud</name><affiliation wicri:level="1"><nlm:affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan</wicri:regionArea><wicri:noRegion>Kazan</wicri:noRegion></affiliation></author></analytic><series><title level="j">BioNanoScience</title><idno type="ISSN">2191-1630</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">RNA viruses cause most of the dangerous communicable diseases. Due to their high mutation rates, RNA viruses quickly evade selective pressures and can adapt to a new host. Therefore, new antiviral approaches are urgently needed, which target more than one specific virus variant and which would optimally prevent development of viral resistance. Among the family of coronaviruses (CoV), several human pathogenic strains (HCoV) are known to cause respiratory diseases and are implied in enteric diseases. While most strains contribute to common cold-like illnesses, others lead to severe infections. One of these viruses is the newly emerged (2012), highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) of zoonotic origin. MERS-CoV causes a severe respiratory infection with a high mortality rate of 35 %. There is no specific treatment or infection prevention available. Here, we show that the bacterial ribonuclease Binase is able to inhibit the replication of MERS-CoV and of the low-pathogenic human coronavirus 229E (HCoV-229E) in cell culture. We demonstrate that at non-toxic concentrations, Binase decreased the titers of MERS-CoV and HCoV-229E. On a molecular level, Binase treatment reduced (i) the viral subgenomic RNAs and (ii) the viral nucleocapsidprotein (N) and non-structural protein 13 (nsp13) accumulation. Furthermore, we show that the quantity of the replication/transcription complexes within the infected cells is diminished. Thus, the data obtained might allow further development of new anti-coronaviral approaches affecting viral replication, independent of the specific virus strain.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32219056</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2191-1630</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>BioNanoScience</Title><ISOAbbreviation>Bionanoscience</ISOAbbreviation></Journal><ArticleTitle>A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.</ArticleTitle><Pagination><MedlinePgn>294-299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12668-016-0341-7</ELocationID><Abstract><AbstractText>RNA viruses cause most of the dangerous communicable diseases. Due to their high mutation rates, RNA viruses quickly evade selective pressures and can adapt to a new host. Therefore, new antiviral approaches are urgently needed, which target more than one specific virus variant and which would optimally prevent development of viral resistance. Among the family of coronaviruses (CoV), several human pathogenic strains (HCoV) are known to cause respiratory diseases and are implied in enteric diseases. While most strains contribute to common cold-like illnesses, others lead to severe infections. One of these viruses is the newly emerged (2012), highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) of zoonotic origin. MERS-CoV causes a severe respiratory infection with a high mortality rate of 35 %. There is no specific treatment or infection prevention available. Here, we show that the bacterial ribonuclease Binase is able to inhibit the replication of MERS-CoV and of the low-pathogenic human coronavirus 229E (HCoV-229E) in cell culture. We demonstrate that at non-toxic concentrations, Binase decreased the titers of MERS-CoV and HCoV-229E. On a molecular level, Binase treatment reduced (i) the viral subgenomic RNAs and (ii) the viral nucleocapsidprotein (N) and non-structural protein 13 (nsp13) accumulation. Furthermore, we show that the quantity of the replication/transcription complexes within the infected cells is diminished. Thus, the data obtained might allow further development of new anti-coronaviral approaches affecting viral replication, independent of the specific virus strain.</AbstractText><CopyrightInformation>© Springer Science+Business Media New York 2016.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Christin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</Affiliation><Identifier Source="ISNI">0000 0001 2165 8627</Identifier><Identifier Source="GRID">grid.8664.c</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulyanova</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</Affiliation><Identifier Source="GRID">grid.77268.3c</Identifier><Identifier Source="ISNI">0000 0004 0543 9688</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilinskaya</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</Affiliation><Identifier Source="GRID">grid.77268.3c</Identifier><Identifier Source="ISNI">0000 0004 0543 9688</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pleschka</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>2Institute of Medical Virology, Justus Liebig University, Schubertstrasse 81, 35392 Giessen, Germany.</Affiliation><Identifier Source="ISNI">0000 0001 2165 8627</Identifier><Identifier Source="GRID">grid.8664.c</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah Mahmud</LastName><ForeName>Raihan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlyovskaya Str, Kazan, 420008 Russia.</Affiliation><Identifier Source="GRID">grid.77268.3c</Identifier><Identifier Source="ISNI">0000 0004 0543 9688</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bionanoscience</MedlineTA><NlmUniqueID>101590778</NlmUniqueID><ISSNLinking>2191-1630</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral agent</Keyword><Keyword MajorTopicYN="N">Binase</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Ribonuclease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32219056</ArticleId><ArticleId IdType="doi">10.1007/s12668-016-0341-7</ArticleId><ArticleId IdType="pii">341</ArticleId><ArticleId IdType="pmc">PMC7090624</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2007 Oct 5;361(4):1000-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17689490</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Feb;84(4):2134-49</Citation><ArticleIdList><ArticleId IdType="pubmed">20007278</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Appl Microbiol. 2016 Sep 12;62(4):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27373509</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Open Bio. 2016 Jan 19;6(1):24-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27047739</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2006 Aug 31;3:63</Citation><ArticleIdList><ArticleId IdType="pubmed">16945126</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antibiot Khimioter. 1990 Mar;35(3):27-31</Citation><ArticleIdList><ArticleId IdType="pubmed">2360851</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Naturae. 2013 Oct;5(4):44-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24455182</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 Jan 23;10(1):e0116917</Citation><ArticleIdList><ArticleId IdType="pubmed">25615576</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Nov;81(22):12323-36</Citation><ArticleIdList><ArticleId IdType="pubmed">17855519</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Toxicon. 2013 Jul;69:219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23567038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antibiotiki. 1981 Jul;26(7):527-32</Citation><ArticleIdList><ArticleId IdType="pubmed">6267996</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-2315</Citation><ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Microbiol. 2014 Jun 17;5:296</Citation><ArticleIdList><ArticleId IdType="pubmed">24987391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS J. 2011 Oct;278(19):3633-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21824291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Russie</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Muller, Christin" sort="Muller, Christin" uniqKey="Muller C" first="Christin" last="Müller">Christin Müller</name></noRegion><name sortKey="Pleschka, Stephan" sort="Pleschka, Stephan" uniqKey="Pleschka S" first="Stephan" last="Pleschka">Stephan Pleschka</name></country><country name="Russie"><noRegion><name sortKey="Ulyanova, Vera" sort="Ulyanova, Vera" uniqKey="Ulyanova V" first="Vera" last="Ulyanova">Vera Ulyanova</name></noRegion><name sortKey="Ilinskaya, Olga" sort="Ilinskaya, Olga" uniqKey="Ilinskaya O" first="Olga" last="Ilinskaya">Olga Ilinskaya</name><name sortKey="Shah Mahmud, Raihan" sort="Shah Mahmud, Raihan" uniqKey="Shah Mahmud R" first="Raihan" last="Shah Mahmud">Raihan Shah Mahmud</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32219056
|texte= A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32219056" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |